It has been reported that dysregulation of the Akt/mTOR pathway plays a key role in the initiation and progression of different forms of cancer [16] and, therefore, we studied the effects of treatment with 2DG, metformin and their combination on the Akt/mTOR pathway in MMECs (Figure 3). This evidence concerns the gene AKT1 and cancer.